The Cure's patience is the product, and it only works because the music earns it

How do you keep an audience hooked for years without releasing a single new note? If you're Robert Smith, you just keep promising. And the strange thing is that it works.

Here is where things stand. In a message for Nick Grimshaw's BBC Radio 6 show, Smith said he is looking forward to "more Cure concerts in 2027," adding that he can't say where or when yet but is "confident they will be bursting with new songs," as NME reports. The band spent the summer on the road behind Songs of a Lost World, and Smith has said that the two albums they've been working on are "done." One is darker, the other "poppy."

That is the whole news: no dates, no titles, no release windows. And yet it is trending. That tells you something about how this band operates.

Scarcity is the strategy, whether or not it was planned

The timeline is almost comic. As far back as 2020, Smith told NME to expect "two new albums and an album of noise." Songs of a Lost World arrived in 2024 after a 16-year gap, per bgnes. The band reportedly recorded 13 songs at Rockfield Studios in March 2025, and by NME's account none of that material has been played live yet.

Most acts would be punished for this. In an era when pop stars feed the algorithm weekly, a band that says "soon" for six years should vanish. Instead, every scrap of news becomes an event, because nothing is oversupplied. We think this is the real lesson for legacy acts: their advantage isn't nostalgia, it's the fact that they can't be replaced on a schedule. A Cure announcement is rare enough to feel like weather.

We'd also be cynical to call it pure calculation. Smith has always seemed temperamentally allergic to hurry. The brilliance is that the temperament and the business model happen to point in the same direction.

The wait only pays off if the record delivers

Scarcity is a loan, not a gift. Each year of "virtually finished" raises the bar. What spared The Cure on the last round was that the album was good enough to settle the debt. NME gave it five stars and argued it felt "sufficient enough for the wait we've endured." That is a rare thing to be able to say after 16 years, and it is the reason the current drip-feed is credible rather than exhausting.

The risk now is different. Smith describes the first new record as quite dark, "more dismal" than the last one, albeit with a different perspective, and the other as his idea of "Cure Pop," which he places about 20 BPM slower than anything Olivia Rodrigo does. Those are intriguing pitches, but they're pitches. We haven't heard a note. Our view: a second dark album right after a career-capping dark album is the harder sell, and the poppy one could be the more interesting gamble.

Putting new songs in the setlist is the bravest part

"Bursting with new songs" is the line we'd underline. Legacy tours usually run on the hits, with the new material tolerated as bathroom-break territory. Promising a set weighted toward unreleased songs, as a band approaching its 50th anniversary in 2028, is a statement of confidence. It also quietly turns the tour into the album launch, which is a smart way to make fans invest in songs before they can stream them.

It's also a gamble. Some of the crowd will want the classics, and a sprawling set of unknown material can deflate a big festival field. But a band that has earned this much patience can afford to spend some of it.

One caution for readers: forecasts about "worldwide tours" and "return to roots" floating around the web are rumor. At least one aggregator has already flagged its own claim as unfounded. Wait for actual dates.

Verdict

The Cure's patience is a brand, and a smart one, but it's an honor system. Fans extend credit because the last record paid it back. If you're a fan, keep your expectations at "interesting" rather than "miraculous," and don't buy anything until dates are official. If you run a legacy act, take notes: you don't need constant output, you need a reason for every gap. So far, Smith has one.